Abstract
Despite improvements in survival after the introduction of chemo-radiotherapy (CRT) in the treatment of patients with cervical cancer, loco-regional control of this disease continues to be a major problem. The present article reviews current and emerging therapeutic strategies combining CRT with novel molecular agents that specifically target the abnormal tumor microenvironment, with the aim of improving local control and survival in patients with locally advanced cervix cancer. The evidence supporting the biological rational to combine novel non-cytotoxic agents with CRT is strong, and drugs targeting different molecular pathways are currently under clinical development (EGFR inhibitors, COX-2 inhibitors, hypoxia targeted agents, etc). Early pre-clinical and clinical strategies also favor the use of vascular-targeted agents with the aim to normalize the abnormal tumor vasculature, increase tumor oxygenation, and reduce interstitial fluid pressure (IFP). The integration of these novel targeted therapies with CRT in clinical trials is discussed, as well as new and promising biomarkers to test drug activity.
Keywords: Molecular targets, chemo-radiation, cervix cancer, hypoxia, IFP
Reviews on Recent Clinical Trials
Title: Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Volume: 3 Issue: 2
Author(s): F. G. Herrera, L. Vidal, A. Oza, M. Milosevic and A. Fyles
Affiliation:
Keywords: Molecular targets, chemo-radiation, cervix cancer, hypoxia, IFP
Abstract: Despite improvements in survival after the introduction of chemo-radiotherapy (CRT) in the treatment of patients with cervical cancer, loco-regional control of this disease continues to be a major problem. The present article reviews current and emerging therapeutic strategies combining CRT with novel molecular agents that specifically target the abnormal tumor microenvironment, with the aim of improving local control and survival in patients with locally advanced cervix cancer. The evidence supporting the biological rational to combine novel non-cytotoxic agents with CRT is strong, and drugs targeting different molecular pathways are currently under clinical development (EGFR inhibitors, COX-2 inhibitors, hypoxia targeted agents, etc). Early pre-clinical and clinical strategies also favor the use of vascular-targeted agents with the aim to normalize the abnormal tumor vasculature, increase tumor oxygenation, and reduce interstitial fluid pressure (IFP). The integration of these novel targeted therapies with CRT in clinical trials is discussed, as well as new and promising biomarkers to test drug activity.
Export Options
About this article
Cite this article as:
Herrera G. F., Vidal L., Oza A., Milosevic M. and Fyles A., Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer, Reviews on Recent Clinical Trials 2008; 3 (2) . https://dx.doi.org/10.2174/157488708784223835
DOI https://dx.doi.org/10.2174/157488708784223835 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Functional Properties of Kefiran in the Medical Field and Food Industry
Current Pharmaceutical Biotechnology Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Critical Role of Hypoxia Sensor - HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing
Current Medicinal Chemistry Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Strategic Nanoparticle-Mediated Gene Transfer in Plants and Animals - a Novel Approach
Current Nanoscience A Review of Bisindolylmethane as an Important Scaffold for Drug Discovery
Current Medicinal Chemistry The Role of ABCG2 and ABCB6 in Porphyrin Metabolism and Cell Survival
Current Pharmaceutical Biotechnology The Effectiveness of Condoms for the Prevention of Sexually Transmitted Diseases
Current Women`s Health Reviews A Concise Review on Multidimensional Silver Nanoparticle Health Aids and Threats
Current Drug Therapy HPV Screening: Available Data and Recommendations for Clinical Practice
Current Cancer Therapy Reviews The mRNA-HPV Test Utilization in the Follow Up of HPV Related Cervical Lesions
Current Pharmaceutical Design CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Novel Insights Into c-Src
Current Pharmaceutical Design Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Natural Thiazoline-Based Cyclodepsipeptides from Marine Cyanobacteria: Chemistry, Bioefficiency and Clinical Aspects
Current Medicinal Chemistry Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery